Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia
Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia
复制标题
DOI：
10.1182/blood-2003-06-1840
复制
发表时间：
2004-04-01
期刊：
影响因子：
20.3
通讯作者：
Albitar, M
中科院分区：
文献类型：
--
作者：
Rogers, A;Joe, Y;Albitar, M
利用杂合性缺失（LOH）和x染色体失活，我们比较了外周血（PB）血浆和骨髓（BM）细胞在检测急性髓性白血病（AML）和骨髓增生异常综合征（MDS）患者基因组异常方面的作用。我们在所有45例有细胞遗传学记录的染色体异常(5q(-), 7（-), +8, 17（-）或20(-)）的患者的PB血浆中检测LOH。来自同一患者的骨髓细胞在89%的MDS患者和70%的AML患者中显示LOH。其中16例患者的治疗后样本显示，在15例样本中，LOH和细胞遗传学在检测残留疾病方面完全一致。16例样本中，4例在BM形态正常的血浆中显示LOH。通过x染色体失活，26份BM样品中有19份（73%）检测到克隆性，而所有PB血浆样品均显示克隆性。这些数据支持PB血浆富含肿瘤特异性DNA的结论，可以替代BM细胞用于研究基因组异常。(C) 2004年由美国血液病学会出版。
Using loss of heterozygosity (LOH) and X-chromosome inactivation, we compared peripheral blood (PB) plasma with bone marrow (BM) cells in detecting genomic abnormalities in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). We detected LOH in the PB plasma of all 45 patients who had cytogenetically documented chromosomal abnormalities (5q(-), 7(-), +8, 17(-), or 20(-)). BM cells from the same patients showed LOH in 89% of patients with MDS and 70% of patients with AML. Posttherapy samples from 16 of these patients demonstrated complete concordance between LOH and cytogenetics in detecting residual disease in 15 samples. Of the 16 samples, 4 showed LOH in plasma with normal BM morphology. Using X-chromosome inactivation, clonality was detectable in 19 (73%) of 26 BM samples, whereas all PB plasma samples showed clonality. These data support the conclusion that PB plasma is enriched by tumor-specific DNA and can replace BM cells for studying genomic abnormalities. (C) 2004 by The American Society of Hematology.